Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/21/2025

Hepatic Steatosis Management

Clinical Presentation

  • Hepatic steatosis is often asymptomatic, with 60-80% of patients showing no symptoms, according to the Korean Association for the Study of the Liver (KASL) guidelines 1
  • When symptoms occur, they may include fatigue, nausea, muscle pain, arthritis, weight loss, and mild abdominal discomfort 1

Disease Progression and Comorbidities

  • Advanced liver disease, including cirrhosis or complications like portal hypertension, can occur in patients with hepatic steatosis 1
  • Comorbid conditions, such as gallbladder disease, pancreatitis, or other gastrointestinal disorders, should be considered in patients with hepatic steatosis 1
  • Metabolic Associated Steatohepatitis Liver Disease (MASLD) is a condition characterized by hepatic steatosis, inflammation, and fibrosis, often associated with metabolic syndrome, as stated by the European Association for the Study of the Liver and 2, 3, 4

Diagnosis and Evaluation

  • Ultrasound is the first-line investigation for hepatic steatosis, with a sensitivity of 84.8% and specificity of 93.6% for moderate-severe steatosis, as reported by the Journal of the American College of Radiology 5
  • Vibration-controlled transient elastography (VCTE/FibroScan) can be used to diagnose liver fibrosis, with thresholds of <8.0 kPa for low risk, 8.0-12.0 kPa for indeterminate risk, and >12.0 kPa for high risk, as recommended by the European Association for the Study of the Liver 2
  • FIB-4 score calculation can be used to assess the risk of advanced fibrosis, with a score of <1.3 indicating low risk, 1.3-2.67 indicating indeterminate risk, and >2.67 indicating high risk 3, 6
  • Enhanced Liver Fibrosis (ELF) test can be used to assess the risk of advanced fibrosis, with a score of <7.7 indicating low risk, 7.7-9.8 indicating intermediate risk, and >9.8 indicating high risk, according to the American Association for the Study of Liver Diseases 6
  • Magnetic resonance elastography (MRE) can be used to assess liver stiffness, with a score of <2.6 kPa indicating low risk, 2.6-3.6 kPa indicating intermediate risk, and >3.6 kPa indicating high risk, as recommended by the Society of Abdominal Radiology 6
  • The new MASLD terminology includes:

    Term Description
    MASL Metabolic Associated Steatosis Liver (simple steatosis)
    MASH Metabolic Associated Steatohepatitis (steatohepatitis)
    MetALD Metabolic and Alcoholic Liver Disease (for cases where alcohol consumption is higher than allowed for MASLD but lower than that attributed to alcoholic liver disease)

Risk Factors

  • Obesity (BMI >25 kg/m² or >23 kg/m² in Asian populations) is a risk factor for hepatomegaly and steatosis, as stated by the American Gastroenterological Association 2
  • Type 2 diabetes and insulin resistance are associated with an increased risk of hepatomegaly and steatosis 7, 2
  • Dyslipidemia (elevated triglycerides, low HDL) is a risk factor for hepatomegaly and steatosis 2
  • Hypertension (>130/85 mmHg) is a risk factor for hepatomegaly and steatosis 2
  • Significant alcohol intake (>14 drinks/week for women, >21 drinks/week for men) is a risk factor for hepatomegaly and steatosis, as stated by the American Gastroenterological Association 7, 8
  • Genetic variants, such as PNPLA3, TM6SF2, MBOAT7, and GCKR, can increase the risk of hepatic steatosis, as stated by the American Gastroenterological Association 8
  • Hepatitis C virus (particularly genotype 3) directly induces steatosis, as reported by the American Association for the Study of Liver Diseases 2, 9
  • Other conditions associated with steatosis include Wilson's disease, hypobetalipoproteinemia, lysosomal acid lipase deficiency (Wolman disease, CESD), severe malnutrition, parenteral nutrition, rapid weight loss (post-bariatric surgery), hypothyroidism, polycystic ovary syndrome (PCOS), growth hormone deficiency, panhypopituitarism, pregnancy-related conditions (HELLP syndrome, acute fatty liver of pregnancy), and celiac disease 2, 7

Management

  • Control of diabetes, hypertension, and dyslipidemia, as well as abstinence from alcohol or moderation in drinking, is recommended for the management of comorbidities in patients with hepatic steatosis, according to the Korean Association for the Study of the Liver (KASL) guidelines 1
  • The American Heart Association recommends at least 150-300 minutes/week of moderate-intensity exercise for patients with MASLD 2
  • A high-protein diet (1.2-1.5 g/kg/day) and late evening snack are recommended to prevent catabolism and maintain muscle mass 3
  • A caloric intake of at least 35 kcal/kg body weight/day is recommended for patients with MASLD 3
  • GLP-1 receptor agonists (such as semaglutide, liraglutide, and dulaglutide) are recommended for patients with comorbid type 2 diabetes and MASLD 2, 3
  • SGLT2 inhibitors (such as empagliflozin and dapagliflozin) are recommended for patients with comorbid type 2 diabetes and MASLD 3
  • Statins are safe and recommended for patients with MASLD and dyslipidemia, according to cardiovascular risk guidelines 2

Surveillance and Follow-up

  • Regular hepatocellular carcinoma (HCC) surveillance is strongly recommended for patients with cirrhosis, using ultrasound with alpha-fetoprotein every 6 months 2
  • Ultrasound-based HCC surveillance has low sensitivity in obese patients, and adding alpha-fetoprotein measurement is recommended 2
  • Low risk patients (FIB-4 <1.3) should be reassessed every 1-3 years, while intermediate risk patients (FIB-4 1.3-2.67 with VCTE <8.0 kPa) should be reassessed within 1 year, and high risk patients (FIB-4 >2.67 or VCTE ≥8.0 kPa) should be referred to hepatology for further evaluation, as recommended by the American Association for the Study of Liver Diseases and the American Diabetes Association 3, 6, 10
  • Patients with high fibrosis risk require specialist referral and multidisciplinary care, as recommended by the American Diabetes Association 10
  • Regular monitoring is recommended for patients with risk factors, with follow-up intervals of 1-3 years depending on fibrosis risk, although the specific guideline society is not mentioned in the article 9

Pre-Transplant Weight Management

  • Target BMI <40 kg/m² (ideally <35 kg/m²) through dietary modification and supervised exercise is recommended for pre-transplant weight management 2, 3
  • Pharmacological weight-loss strategies may be considered after risk-benefit assessment for pre-transplant weight management 2, 3
  • Sleeve gastrectomy may be considered in compensated cirrhosis without clinically significant portal hypertension (CSPH) for pre-transplant weight management 2, 3

REFERENCES

5

acr appropriateness criteria® abnormal liver function tests. [LINK]

Journal of the American College of Radiology, 2023